Search results
Results from the WOW.Com Content Network
Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) just released its third-quarter report and things are looking bullish. Sales...
Shareholders of Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) will be pleased this week, given that the stock price is up...
Xeris Pharmaceuticals, Inc. (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xeris Pharmaceuticals, Inc. is developing the Glucagon Rescue Pen or G-Pen using a patented non-aqueous formulation of glucagon that is room-temperature stable, low-volume, and pre-mixed in an auto-injectable device (similar to an EpiPen) that takes the injection process down to two steps (as opposed to nine steps with glucagon emergency kits ...
Xeris Pharmaceuticals Inc (NASDAQ: XERS) has entered into an exclusive agreement with Tetris Pharma Limited to commercialize Ogluo in the European Economic Area, the U.K., and Switzerland. Ogluo ...
Glucagon, sold under the brand name Baqsimi among others, is a medication and hormone. [9] As a medication it is used to treat low blood sugar, beta blocker overdose, calcium channel blocker overdose, and those with anaphylaxis who do not improve with epinephrine. [10]
Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.
Xeris Pharmaceuticals Inc (XERS) delivered earnings and revenue surprises of 3.26% and -7.91%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the ...